- Novartis AG NVS announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
- The data showed that the tislelizumab / chemo combo significantly improved overall survival (OS) as a first-line treatment, regardless of PD-L1 status versus chemotherapy.
- Tislelizumab combo demonstrated a median OS of 17.2 months versus 10.6 months in patients receiving chemotherapy plus placebo and reduced the risk of death by 34%.
- Read Next: FDA Approves Novartis' Tafinlar + Mekinist Broadening BRAF/MEK Cancer Combo Use.
- In patients with a PD-L1 score ≥10% (secondary endpoint), tislelizumab plus chemotherapy showed a median OS of 16.6 months versus 10.0 months and reduced the risk of death by 38%.
- Tislelizumab plus chemotherapy also significantly improved progression-free survival (7.3 months vs. 5.6 months) and objective response rate (63.5% vs. 42.4%)
- The incidence of treatment-related adverse events (TRAEs) was similar in both arms. The most common TRAEs for tislelizumab plus chemotherapy were anemia, decreased neutrophils, white blood cell count & appetite, nausea, and peripheral sensory neuropathy.
- In January 2021, BeiGene Ltd BGNE collaborated with Novartis for the clinical development and marketing of tislelizumab in North America, Europe, and Japan.
- Price Action: NVS shares are down 0.97% at $83.95 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
